Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 66

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2017

Summary

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF?) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 7 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Genetic Disorders, Central Nervous System, Gastrointestinal, Hematological Disorders, Metabolic Disorders and Oncology which include indications Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Muscular Dystrophy, Sarcopenia, Anemia, Becker Muscular Dystrophy, Charcot-Marie-Tooth Disease Type I, Crohn's Disease (Regional Enteritis), Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Inclusion Body Myositis (IBM), Insulin Resistance, Muscle Atrophy, Myelodysplastic Syndrome, Myelofibrosis, Sickle Cell Disease, Spinal Muscular Atrophy (SMA) and Thalassemia.

The latest report GrowthDifferentiation Factor 8 - Pipeline Review, H2 2017, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)

- The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects

- The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview 7
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development 19
Acceleron Pharma Inc 19
Amgen Inc 19
Bioleaders Corp 20
F. Hoffmann-La Roche Ltd 20
Pfizer Inc 21
Regeneron Pharmaceuticals Inc 21
Sarepta Therapeutics Inc 22
Scholar Rock Inc 22
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles 23
ACE-083 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
ACE-2494 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ACE-2798 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
ATA-842 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BLS-ILB-MD1 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
domagrozumab - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
luspatercept - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
OSX-200 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
REGN-2477 + trevogrumab - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
RG-6206 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
SRK-015 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
trevogrumab - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products 50
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products 51
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones 52
Featured News & Press Releases 52
Aug 01, 2017: Acceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease 52
Jul 10, 2017: Scholar Rock and the Miami Project to Cure Paralysis Present Preclinical Data Demonstrating Therapeutic Potential of SRK-015 in Spinal Cord Injury at 35th Annual National Neurotrauma Symposium 52
Jun 28, 2017: Scholar Rock to Develop SRK-015 to Improve Muscle Function in Patients with Spinal Muscular Atrophy 53
Jun 23, 2017: Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association 54
Jun 23, 2017: Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association 55
Jun 01, 2017: Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia 57
May 30, 2017: Pfizer Completes Enrollment of Phase 2 Study of Domagrozumab (PF- 06252616) in Duchenne Muscular Dystrophy 58
May 18, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association 58
May 06, 2017: Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes 59
Apr 27, 2017: Acceleron Provides Clinical Development Updates on Luspatercept Program 60
Apr 06, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes 61
Mar 16, 2017: Acceleron Announces Plans to Initiate a Phase 2 Trial of ACE-083 in Charcot-Marie-Tooth Neuromuscular Disease and Host Educational Webinar 61
Dec 22, 2016: Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy 62
Dec 05, 2016: Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology 62
Dec 04, 2016: Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology 63
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Stage and Route of Administration, H2 2017 16
Number of Products by Stage and Molecule Type, H2 2017 18
Pipeline by Acceleron Pharma Inc, H2 2017 19
Pipeline by Amgen Inc, H2 2017 20
Pipeline by Bioleaders Corp, H2 2017 20
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 20
Pipeline by Pfizer Inc, H2 2017 21
Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 21
Pipeline by Sarepta Therapeutics Inc, H2 2017 22
Pipeline by Scholar Rock Inc, H2 2017 22
Dormant Projects, H2 2017 50
Discontinued Products, H2 2017 51

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 15
Number of Products by Stage and Routes of Administration, H2 2017 15
Number of Products by Molecule Types, H2 2017 17
Number of Products by Stage and Molecule Types, H2 2017 17
  • Global Pyrogen Testing Detailed Analysis Report 2017-2022
    Published: 19-Sep-2017        Price: US 3250 Onwards        Pages: 107
    This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Pyrogen Testing industry. This report splits Pyrogen Testing market By Product, By Test, which covers the history data information from 2012 to 2016 and forecast from 2017 to 2022. This report focuses Global market, it covers details a......
  • Global and Europe Pyrogen Testing Market - Analysis and Outlook to 2022
    Published: 19-Sep-2017        Price: US 2960 Onwards        Pages: 110
    This report presents a comprehensive overview of the Pyrogen Testing market in Europe, which shares the history data information from 2012 to 2016, and forecast from 2017 to 2022. This report provides a detailed analysis of the market, including its dynamics, structure, characteristics, main players, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in Pyrogen Testing industry. This report focuses Global......
  • 2017-2022 Global and Japan Pyrogen Testing Market Analysis Report
    Published: 19-Sep-2017        Price: US 3085 Onwards        Pages: 102
    The global Pyrogen Testing market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022. Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%. This report, with focus on top players in the global and Japan, studies the Pyrogen Testing market's development status and future trend in the g......
  • Global Ion Indicators Market Research Report 2017
    Published: 18-Sep-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Ion Indicators market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Ion Indicators in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • Global Ion Indicators Sales Market Report 2017
    Published: 18-Sep-2017        Price: US 4000 Onwards        Pages: 106
    In this report, the global Ion Indicators market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Ion Indicators for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan ......
  • Global Mice Model Market Research Report 2017
    Published: 18-Sep-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Mice Model market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Mice Model in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan ......
  • Global Cytokines Market Research Report 2017
    Published: 15-Sep-2017        Price: US 2900 Onwards        Pages: 116
    In this report, the global Cytokines market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cytokines in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan - ......
  • Global Microbial Products Sales Market Report 2017
    Published: 15-Sep-2017        Price: US 4000 Onwards        Pages: 110
    In this report, the global Microbial Products market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Microbial Products for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan......
  • Global Antibody Engineering Services Market Size, Status and Forecast 2022
    Published: 14-Sep-2017        Price: US 3300 Onwards        Pages: 131
    This report studies the Antibody Engineering Services market status and outlook of global and major regions, from angles of players, regions, product and end Application/industries; this report analyzes the top players in global and major regions, and splits the Antibody Engineering Services market by product and Application/end industries. The global Antibody Engineering Services market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs